Literature DB >> 10536366

Donor variation in the growth properties and osteogenic potential of human marrow stromal cells.

D G Phinney1, G Kopen, W Righter, S Webster, N Tremain, D J Prockop.   

Abstract

Human marrow stromal cells (MSCs) were isolated from posterior illiac crest marrow aspirates obtained from 17 healthy donors, ages 19-45 years, with no apparent physical disability. First passage hMSCs exhibited growth rates in vitro that varied up to 12-fold between donors. No correlation between growth rate and the age or gender of the donor was evident (P </= 0.05). When hMSCs were cultured without passage for eight days (subconfluent cultures) or 22 days (confluent cultures) in the absence of any osteogenic agonists, levels of alkaline phosphatase enzyme activity varied 40-fold and 10-fold, respectively, between donors. When exposed to osteo-inductive media, donor populations also showed dramatic differences in levels of bone-specific gene induction. Collectively, these data demonstrate that hMSC cultures are composed of a heterogeneous mixture of cells at various stages of differentiation and with distinct osteogenic potentials. Differences in both growth rate and ALP activity were evident in hMSC cultures established from multiple aspirates obtained over a six month period from the same donors. Therefore, it appears that cellular heterogeneity produced by the method of harvest is propagated within and among different donor populations during culture expansion in vitro. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536366

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  134 in total

1.  Effects of mechanical strain on human mesenchymal stem cells and ligament fibroblasts in a textured poly(L-lactide) scaffold for ligament tissue engineering.

Authors:  Ludwika Kreja; Astrid Liedert; Heiter Schlenker; Rolf E Brenner; Jörg Fiedler; Benedikt Friemert; Lutz Dürselen; Anita Ignatius
Journal:  J Mater Sci Mater Med       Date:  2012-06-24       Impact factor: 3.896

Review 2.  Stem cell therapy for ischemic heart disease.

Authors:  Mohammad Nurulqadr Jameel; Jianyi Zhang
Journal:  Antioxid Redox Signal       Date:  2010-10-28       Impact factor: 8.401

3.  Runx2 overexpression in bone marrow stromal cells accelerates bone formation in critical-sized femoral defects.

Authors:  Abigail M Wojtowicz; Kellie L Templeman; Dietmar W Hutmacher; Robert E Guldberg; Andrés J García
Journal:  Tissue Eng Part A       Date:  2010-09       Impact factor: 3.845

Review 4.  Mesenchymal stem cells in the pathogenesis and therapy of breast cancer.

Authors:  Christelle P El-Haibi; Antoine E Karnoub
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-12-21       Impact factor: 2.673

5.  Chromatographically isolated CD63+CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI.

Authors:  Dong-ki Kim; Hidetaka Nishida; Su Yeon An; Ashok K Shetty; Thomas J Bartosh; Darwin J Prockop
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-22       Impact factor: 11.205

6.  Dynamic Fluid Flow Mechanical Stimulation Modulates Bone Marrow Mesenchymal Stem Cells.

Authors:  Minyi Hu; Robbin Yeh; Michelle Lien; Morgan Teeratananon; Kunal Agarwal; Yi-Xian Qin
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

Review 7.  Activity of mesenchymal stem cells in therapies for chronic skin wound healing.

Authors:  Austin Nuschke
Journal:  Organogenesis       Date:  2013-12-10       Impact factor: 2.500

8.  Variation in primary and culture-expanded cells derived from connective tissue progenitors in human bone marrow space, bone trabecular surface and adipose tissue.

Authors:  Maha A Qadan; Nicolas S Piuzzi; Cynthia Boehm; Wesley Bova; Malcolm Moos; Ronald J Midura; Vincent C Hascall; Christopher Malcuit; George F Muschler
Journal:  Cytotherapy       Date:  2018-02-01       Impact factor: 5.414

9.  MicroRNA Levels as Prognostic Markers for the Differentiation Potential of Human Mesenchymal Stromal Cell Donors.

Authors:  Nicole Georgi; Hanna Taipaleenmaki; Christian C Raiss; Nathalie Groen; Karolina Janaeczek Portalska; Clemens van Blitterswijk; Jan de Boer; Janine N Post; Andre J van Wijnen; Marcel Karperien
Journal:  Stem Cells Dev       Date:  2015-06-17       Impact factor: 3.272

10.  Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury.

Authors:  Florian Tögel; Arthur Cohen; Ping Zhang; Ying Yang; Zhuma Hu; Christof Westenfelder
Journal:  Stem Cells Dev       Date:  2009-04       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.